Vivos Therapeutics (NASDAQ:VVOS) Price Target Lowered to $6.00 at Alliance Global Partners

Vivos Therapeutics (NASDAQ:VVOS) had its price target decreased by research analysts at Alliance Global Partners from $8.25 to $6.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Alliance Global Partners’ target price would suggest a potential upside of 115.05% from the company’s previous close.

Separately, Ascendiant Capital Markets lifted their target price on Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a report on Tuesday, August 20th.

Vivos Therapeutics Stock Performance

NASDAQ:VVOS traded up $0.08 during trading hours on Tuesday, reaching $2.79. The stock had a trading volume of 79,313 shares, compared to its average volume of 481,448. The stock has a market capitalization of $13.29 million, a PE ratio of -0.49 and a beta of 7.71. Vivos Therapeutics has a 52 week low of $1.91 and a 52 week high of $48.79. The company has a 50 day moving average price of $2.79 and a two-hundred day moving average price of $2.52.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.